EDAP TMS(EDAP)
69120 VAULX EN VELIN, FranceBiotechnology
Focus: EDAP TMS is a publicly-traded medical device company specializing in high-intensity focused ultrasound (HIFU) technology for oncology and women's health applications. The company generates ~$69M in annual revenue with a focused pipeline centered on prostate cancer and endometriosis treatments.
Profile data last refreshed 15h ago · AI intelligence enriched 3d ago
Funding Stage
PUBLIC
Open Jobs
0
About EDAP TMS
AI assessmentNot HiringNo open roles listed right now. Follow EDAP TMS to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from EDAP TMS's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
12 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$69M
Pipeline & Clinical Trials
HIFU treatment in rectal Endometriosis
EndometriosisClinical Trials (1)
NCT05755958Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.
N/AHelp build intelligence for EDAP TMS
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.